Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer.

ABSTRACT:

Background

Current breast cancer (BC) diagnostics include detailed pathological and genetic analysis for biological subtype identification; however, throughout the course of the disease, new alterations determining the progression of the disease or resistance to treatment appear. The tests based on liquid biopsy allow minimally invasive real-time monitoring of tumour-specific alteration during the entire disease treatment. Tumour-specific genetic material fragments occur in bodily fluids, and cell-free nucleic acids are a convenient tool for analysing genetic and epigenetic changes in tumours. Evidence for the diagnostic and prognostic value of epigenetic biomarkers is gradually increasing. Although, up to date, there is limited access to in vitro diagnostic (IVD) epigenetic

SUBMITTER: Sadzeviciene I 

PROVIDER: S-EPMC12285340 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature